Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Asna Amin, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Mark G. Carmichael, Matthew Timothy Hueman, Elizabeth A. Mittendorf, Catherine E. Storrer, Yusuf H. Jama, Dianna Craig, Alex Stojadinovic, Sathibalan Ponniah, George E. Peoples

Research output: Contribution to journalArticle

Abstract

Background: E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups. Methods: Among the 186 BCa patients enrolled, 177 completed the study. Patients were HLA typed; the HLA-A2+/A3+ patients were vaccinated; HLA-A2-/A3- patients were followed as controls. Standard clinicopathological factors, immunologic response to the vaccine, and recurrences were collected and assessed. Results: The control group recurrence rate was 14.8 and 8.3% in the vaccinated group (P = 0.17). Comparing the 8 vaccinated recurrences (V-R) to the 88 vaccinated nonrecurrent patients (V-NR), the V-R group had higher nodal stage (≥N2: 75 vs. 5%, P = 0.0001) and higher grade tumors (%grade 3: 88 vs. 31%, P = 0.003). The V-R group did not fail to respond immunologically as noted by equivalent dimer responses and post-DTH responses. Compared to control recurrent patients (C-R), V-R patients trended toward higher-grade tumors and hormone-receptor negativity. C-R patients had 50% bone-only recurrences, compared to V-R patients with no bone-only recurrences (P = 0.05). Lastly, V-R mortality rate was 12.5% compared with 41.7% for the C-R group (P = 0.3). Conclusions: The vaccinated patients who recurred had more aggressive disease compared to V-NR patients. V-R patients had no difference in immune response to the vaccine either in vitro or in vivo. V-R patients, when compared to C-R patients, trended towards more aggressive disease, decreased recurrence rates, decreased mortality, and no bone-only recurrences.

Original languageEnglish (US)
Pages (from-to)1817-1825
Number of pages9
JournalCancer Immunology Immunotherapy
Volume57
Issue number12
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Subunit Vaccines
Vaccination
Clinical Trials
Recurrence
Neoplasms
Vaccines
HLA-A3 Antigen
HLA-A2 Antigen
Breast Neoplasms
Bone and Bones
Control Groups
Mortality

Keywords

  • E75 peptide
  • Immunologic response
  • Pathologic patterns
  • Preventive
  • Recurrence
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. / Amin, Asna; Benavides, Linda C.; Holmes, Jarrod P.; Gates, Jeremy D.; Carmichael, Mark G.; Hueman, Matthew Timothy; Mittendorf, Elizabeth A.; Storrer, Catherine E.; Jama, Yusuf H.; Craig, Dianna; Stojadinovic, Alex; Ponniah, Sathibalan; Peoples, George E.

In: Cancer Immunology Immunotherapy, Vol. 57, No. 12, 12.2008, p. 1817-1825.

Research output: Contribution to journalArticle

Amin, Asna ; Benavides, Linda C. ; Holmes, Jarrod P. ; Gates, Jeremy D. ; Carmichael, Mark G. ; Hueman, Matthew Timothy ; Mittendorf, Elizabeth A. ; Storrer, Catherine E. ; Jama, Yusuf H. ; Craig, Dianna ; Stojadinovic, Alex ; Ponniah, Sathibalan ; Peoples, George E. / Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. In: Cancer Immunology Immunotherapy. 2008 ; Vol. 57, No. 12. pp. 1817-1825.
@article{6b82e0fad47c4006ad8acfe70cae26c4,
title = "Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02",
abstract = "Background: E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups. Methods: Among the 186 BCa patients enrolled, 177 completed the study. Patients were HLA typed; the HLA-A2+/A3+ patients were vaccinated; HLA-A2-/A3- patients were followed as controls. Standard clinicopathological factors, immunologic response to the vaccine, and recurrences were collected and assessed. Results: The control group recurrence rate was 14.8 and 8.3{\%} in the vaccinated group (P = 0.17). Comparing the 8 vaccinated recurrences (V-R) to the 88 vaccinated nonrecurrent patients (V-NR), the V-R group had higher nodal stage (≥N2: 75 vs. 5{\%}, P = 0.0001) and higher grade tumors ({\%}grade 3: 88 vs. 31{\%}, P = 0.003). The V-R group did not fail to respond immunologically as noted by equivalent dimer responses and post-DTH responses. Compared to control recurrent patients (C-R), V-R patients trended toward higher-grade tumors and hormone-receptor negativity. C-R patients had 50{\%} bone-only recurrences, compared to V-R patients with no bone-only recurrences (P = 0.05). Lastly, V-R mortality rate was 12.5{\%} compared with 41.7{\%} for the C-R group (P = 0.3). Conclusions: The vaccinated patients who recurred had more aggressive disease compared to V-NR patients. V-R patients had no difference in immune response to the vaccine either in vitro or in vivo. V-R patients, when compared to C-R patients, trended towards more aggressive disease, decreased recurrence rates, decreased mortality, and no bone-only recurrences.",
keywords = "E75 peptide, Immunologic response, Pathologic patterns, Preventive, Recurrence, Vaccine",
author = "Asna Amin and Benavides, {Linda C.} and Holmes, {Jarrod P.} and Gates, {Jeremy D.} and Carmichael, {Mark G.} and Hueman, {Matthew Timothy} and Mittendorf, {Elizabeth A.} and Storrer, {Catherine E.} and Jama, {Yusuf H.} and Dianna Craig and Alex Stojadinovic and Sathibalan Ponniah and Peoples, {George E.}",
year = "2008",
month = "12",
doi = "10.1007/s00262-008-0509-2",
language = "English (US)",
volume = "57",
pages = "1817--1825",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",

}

TY - JOUR

T1 - Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine

T2 - From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

AU - Amin, Asna

AU - Benavides, Linda C.

AU - Holmes, Jarrod P.

AU - Gates, Jeremy D.

AU - Carmichael, Mark G.

AU - Hueman, Matthew Timothy

AU - Mittendorf, Elizabeth A.

AU - Storrer, Catherine E.

AU - Jama, Yusuf H.

AU - Craig, Dianna

AU - Stojadinovic, Alex

AU - Ponniah, Sathibalan

AU - Peoples, George E.

PY - 2008/12

Y1 - 2008/12

N2 - Background: E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups. Methods: Among the 186 BCa patients enrolled, 177 completed the study. Patients were HLA typed; the HLA-A2+/A3+ patients were vaccinated; HLA-A2-/A3- patients were followed as controls. Standard clinicopathological factors, immunologic response to the vaccine, and recurrences were collected and assessed. Results: The control group recurrence rate was 14.8 and 8.3% in the vaccinated group (P = 0.17). Comparing the 8 vaccinated recurrences (V-R) to the 88 vaccinated nonrecurrent patients (V-NR), the V-R group had higher nodal stage (≥N2: 75 vs. 5%, P = 0.0001) and higher grade tumors (%grade 3: 88 vs. 31%, P = 0.003). The V-R group did not fail to respond immunologically as noted by equivalent dimer responses and post-DTH responses. Compared to control recurrent patients (C-R), V-R patients trended toward higher-grade tumors and hormone-receptor negativity. C-R patients had 50% bone-only recurrences, compared to V-R patients with no bone-only recurrences (P = 0.05). Lastly, V-R mortality rate was 12.5% compared with 41.7% for the C-R group (P = 0.3). Conclusions: The vaccinated patients who recurred had more aggressive disease compared to V-NR patients. V-R patients had no difference in immune response to the vaccine either in vitro or in vivo. V-R patients, when compared to C-R patients, trended towards more aggressive disease, decreased recurrence rates, decreased mortality, and no bone-only recurrences.

AB - Background: E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups. Methods: Among the 186 BCa patients enrolled, 177 completed the study. Patients were HLA typed; the HLA-A2+/A3+ patients were vaccinated; HLA-A2-/A3- patients were followed as controls. Standard clinicopathological factors, immunologic response to the vaccine, and recurrences were collected and assessed. Results: The control group recurrence rate was 14.8 and 8.3% in the vaccinated group (P = 0.17). Comparing the 8 vaccinated recurrences (V-R) to the 88 vaccinated nonrecurrent patients (V-NR), the V-R group had higher nodal stage (≥N2: 75 vs. 5%, P = 0.0001) and higher grade tumors (%grade 3: 88 vs. 31%, P = 0.003). The V-R group did not fail to respond immunologically as noted by equivalent dimer responses and post-DTH responses. Compared to control recurrent patients (C-R), V-R patients trended toward higher-grade tumors and hormone-receptor negativity. C-R patients had 50% bone-only recurrences, compared to V-R patients with no bone-only recurrences (P = 0.05). Lastly, V-R mortality rate was 12.5% compared with 41.7% for the C-R group (P = 0.3). Conclusions: The vaccinated patients who recurred had more aggressive disease compared to V-NR patients. V-R patients had no difference in immune response to the vaccine either in vitro or in vivo. V-R patients, when compared to C-R patients, trended towards more aggressive disease, decreased recurrence rates, decreased mortality, and no bone-only recurrences.

KW - E75 peptide

KW - Immunologic response

KW - Pathologic patterns

KW - Preventive

KW - Recurrence

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=52549085726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52549085726&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0509-2

DO - 10.1007/s00262-008-0509-2

M3 - Article

C2 - 18392824

AN - SCOPUS:52549085726

VL - 57

SP - 1817

EP - 1825

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 12

ER -